MedWatch

Orphazyme launches investigation into dramatic and mysterious share price roller coaster

Orphazyme experienced significant turbulence on the US market on Thursday, where share price increases peaked at 1,400 percent with no explanation or forewarning. This rubbed off on the Danish exchange on Friday.

Photo: Orphazyme/PR

Prices of shares in biotech company Orphazyme have been through an inexplicable roller coaster since Thursday.

Orphazyme is listed on the Danish and US stock exchange, and its share price started fluctuating wildly in the US on Thursday when the share price skyrocketed, rising by almost 1,400 percent at one point. Trading was suspended 20 times, and it all ended with a 300 percent increase.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs